Augmentation of clozapine with another pharmacological agent: Treatment for refractory schizophrenia in the 'real world'

Acta Psychiatrica Scandinavica

Volumn 126, Issue 1, 2012, Pages 40-46

  Pai, N B ^a   Laidlaw, M ^b   Vella, S L ^a  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b Illawarra Shoalhaven Local Hospital District   (Australia)

Author keywords

Antipsychotics; Clinical aspects; Schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIMETABOLITE; BENZODIAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; MISCELLANEOUS DRUGS AND AGENTS; MOOD STABILIZER; NEUROLEPTIC AGENT;

ARTICLE; CLINICAL ASSESSMENT; CROSS-SECTIONAL STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHYSICIAN; PREVALENCE; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; AUSTRALIA; CLOZAPINE; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PSYCHOTROPIC DRUGS; SCHIZOPHRENIA;

EID: 84862147219     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2012.01854.x     Document Type: Article

References (28)

1. Vella S, Pai N. A pharmacoepidemiological analysis of clozapine use in a region of Australia. Acta Psychiatr Scand 2011;124:413-414.
2. Pai N, Vella S. Reason for clozapine cessation. Acta Psychiatr Scand 2012;125:39-44.
3. Semiz UB, Cetin M, Basoglu C et al. Clinical predictors of therapeutic response to clozapine in a sample of Turkish patients with treatment-resistant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:1330-1336.
4. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry, 1988;45:789-796.
5. Sommer IE, Begemann MJH, Temmerman A, Leucht S. Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophr Bull 2011; doi: [Epub ahead of print].
6. Wheeler A, Humberstone V, Robinson G. Outcomes for schizophrenia patients with clozapine treatment: how good does it get? J Psychopharmacol 2009;23:957-965.
7. Vella S, Pai N. Psychosocial and biological factors contributing to body weight gain in schizophrenia. Online J Health Allied Sci 2011;10:1.
8. Holt RIG, Peveler RC. Obesity, serious mental illness and antipsychotic drugs. Diabetes Obes Metab 2009;11:665-679.
9. Kim SH, Jung DC, Ahn YM, Kim YS. The combined use of risperidone long-acting injection and clozapine in patients with schizophrenia non-adherent to clozapine: a case series. J Psychopharmacol 2010;24:981-986.
10. Craddock N, Antebi D, Attenburrow MJ et al. Wake-up call for British psychiatry. B J Psychiatry 2008;193:6-9.
11. Druss BG, Von Esenwein SA. Improving general medical care for persons with mental and addictive disorders: systematic review. Gen Hosp Psychiatry 2006;28:145-153.
12. Nielsen J, Dahm M, Lublin H, Taylor D. Psychiatrists attitude towards and knowledge of clozapine treatment. J Psychopharmacol 2010;24:965-971.
13. Cipriani A, Boso M, Barbui C. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database Syst Rev 2009;3: Art. No. CD006324. DOI:
14. Remington G, Saha A, Chong SA, Shammi C. Augmentation strategies in clozapine-resistant schizophrenia. CNS Drugs 2005;19:843-872.
15. Buchanan RW, Kreyenbuhl J, Kelly DL et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010;36:71-93.
16. Nielsen J, Damkier P, Lublin H, Taylor D. Optimizing clozapine treatment. Acta Psychiatr Scand 2011;123:411-422.
17. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia, 2nd edn. Arlington (VA): American Psychiatric Association, 2004
18. Porcelli S, Balzarro B, Serreti A. Clozapine resistance: augmentation strategies. Eur Neuropsychopharmacol 2012;22:165-182.
19. Barbui C, Signoretti A, Mule S, Boso M, Cipriani A. Does the addition of a second antipsychotic drug improve clozapine treatment? Schizophr Bull 2011;35:458-468.
20. Taylor DM, Smith L. Augmentation of clozapine with a second antipsychotic - a meta-analysis of randomized, placebo-controlled studies. Acta Psychiatr Scand 2009;119:419-425.
21. De Risio A, Pancheri A, Simonetti G, Giannarelli D, Stefanutto L, Gentile B. Add-on of aripiprazole improves outcome in clozapine-resistant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:1112-1116.
22. Weiden PJ, Solari H, Kim S, Bishop JR. Long-acting injectable antipsychotics and the management of nonadherence. Psychiatric Ann 2011;41:271-278.
23. Neilsen J, Skadhede S, Correll CU. Antipsychotics associated with the development of type 2 diabetes in anti-psychotic naive patients. Neuropsychopharmacology 2010;35:1997-2004.
24. Baptista T, Rangel N, Fernandez V et al. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial. Schizophr Res 2007;93:99-108.
25. Wu R, Zhao J, Jin H et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA 2008;299:185-193.
26. Morrato EH, Druss B, Hartung DM et al. Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Arch Gen Psychiatry 2010;67:17-24.
27. Waterreus AJ, Laughame JDE. Screening for the metabolic syndrome in patients receiving antipsychotic treatment: a proposed algorithm. Med J Aust 2009;190:185-189.
28. John AP, Koloth R, Dragovic M, Lim SCB. Prevalence of metabolic syndrome among Australians with severe mental illness. Med J Aust 2009;190:176-179.